Staphylococcus aureus is the causative agent of many diseases, including meningitis, bacteraemia, pneumonia, food poisoning and toxic shock syndrome. Structural characterization of the PaaI-like thioesterase SAV0944 (SaPaaI) from S. aureus subsp. aureus Mu50 will aid in understanding its potential as a new therapeutic target by knowledge of its molecular details and cellular functions. Here, the recombinant expression, purification and crystallization of SaPaaI thioesterase from S. aureus are reported. This protein initially crystallized with the ligand coenzyme A using the hanging-drop vapour-diffusion technique with condition No. 40 of Crystal Screen from Hampton Research at 296 K. Optimal final conditions consisting of 24% PEG 4000, 100 mM sodium citrate pH 6.5, 12% 2-propanol gave single diffraction-quality crystals. These crystals diffracted to beyond 2 Å resolution at the Australian Synchrotron and belonged to space group P12 1 1, with unit-cell parameters a = 44.05, b = 89.05, c = 60.74 Å , = 100.5 . Initial structure determination and refinement gave an R factor and R free of 17.3 and 22.0%, respectively, confirming a positive solution in obtaining phases using molecular replacement.
Introduction
Staphylococcus aureus is a Gram-positive bacterium which is both pathogenic and commensal to humans. Whilst it resides with no harm in $20% of the general population, it is also the causative agent of many diseases ranging from minor to life-threatening, with the latter including meningitis, bacteraemia, pneumonia, food poisoning and toxic shock syndrome. It is also a notorious causative of nosocomial infections in hospitals around the world (Klevens et al., 2008) . S. aureus-mediated bacteraemia, particularly involving methicillinresistant (MR) strains, has increased in recent years even in developed countries such as the United States, European countries, Australia and New Zealand (Collignon et al., 2005; Shorr & Lodise, 2006; European Antimicrobial Resistance Surveillance System, 2006) .
Prior to the introduction of antibiotics, the mortality rate owing to S. aureus infection was 90%. Even in the post-antibiotic era, fatality rates have reached 30%, which is mostly attributable to the emergence of methicillin-resistant S. aureus (MRSA) and vancomycinresistant S. aureus (VRSA) infections (World Health Organization, 2013) . The increasing emergence of MRSA and VRSA demonstrates the urgent need for the development of new antimicrobial agents.
Understanding molecular details and cellular function through protein X-ray crystallography provides the potential for the development of new therapeutics. Here, we report the crystallization of PaaI-like thioesterase (SaPaaI), a protein that belongs to the aminoacid transport and metabolism gene cluster from S. aureus subsp. aureus Mu50. PaaI thioesterase catalyses the cleavage of CoA from phenylacetyl-CoA and hydroxyphenylacetyl-CoA substrates formed in the phenylacetate pathway. The functionality of the phenylacetate pathway of Burkholderia cenocepacia proved to be responsible for full pathogenicity when studied in a Caenorhabditis elegans host model (Law et al., 2008) . The general functions of acyl-CoA thioesterase involve the release of the carboxylate unit for degradation, regulation of cellular pathways and release of CoA for use in other reactions (Hunt & Alexson, 2002; Kirkby et al., 2010) . PaaI thio-esterase is a member of the hotdog-fold thioesterase family, which includes 4-hydroxybenzoyl-CoA thioesterase, but is able to recognize phenylacetyl-CoA as substrate rather than benzoyl-CoA (Song et al., 2006) . The crystallization and preliminary diffraction analysis of SaPaaI will enable its high-resolution structure determination and will enable the characterization of its involvement in possible roles in amino-acid transport and metabolism, which in turn has the potential to assist in rational drug design against this pathogen.
Methods

Cloning
The 375 bp open reading frame (sav0944) encoding SaPaaI was amplified by polymerase chain reaction using S. aureus subsp. aureus Mu50 genomic DNA as a template (ATCC 700699D-5). The PCRamplified product was then cloned into expression vector pMCSG21 using ligation-independent cloning. Briefly, this involved amplification of the sav0944 gene with the forward and reverse primers TACTTCCAATCCAATGCCATGACTCATTTATTAGAGACATT-TGAG and TTATCCACTTCCAATGTTATTATTTTAAAGGTTT-AATAGCAACTGTAC, respectively, where the bold nucleotides are required for the ligation-independent cloning (LIC) procedure and the underlined nucleotides are complementary to the gene nucleotide sequence. Following the purification of amplified PCR product using a Qiagen PCR purification kit, the gene was cloned into SspI-and T4 polymerase-treated pMCSG21 expression vector. Confirmed clones by colony PCR were sent to the Australian Genome Research Facility (AGRF) for DNA sequencing to ensure the fidelity of the gene sequence. BioEdit and ClustalW were used to analyse the nucleotide sequences.
Expression and purification
The cloned SaPaaI allowed the recombinant expression of an N-terminal His 6 -SaPaaI fusion protein in Escherichia coli BL21 (DE3) pLysS cells. A single colony of transformed E. coli BL21 (DE3) pLysS cells was grown to saturation in a 5 ml primary culture in Luria-Bertani (LB) broth overnight. Subsequently, 1 ml of this primary culture was used to inoculate 500 ml auto-induction medium (Studier, 2005) containing 100 mg ml À1 spectinomycin, and the culture was incubated in a shaker incubator at 298 K for 24 h. Following centrifugation, the cell pellet was resuspended in 1/10 the volume of His buffer A (50 mM phosphate buffer pH 8.0, 300 mM NaCl, 20 mM imidazole) and stored at 253 K. Three freeze-thaw cycles and the addition of lysozyme (1 ml of a 20 mg ml À1 stock) was used to lyse the cells, and centrifugation at 20 000g was used to remove cellular debris. The protein supernatant extract was loaded onto a 5 ml His column (HisTrap HP, GE Healthcare) using FPLC at room temperature, washed in His buffer A and eluted using a ten-column-volume gradient to 100% His buffer B (50 mM phosphate buffer pH 8.0, 300 mM NaCl, 500 mM imidazole). Tobacco etch virus (TEV) protease was incubated for 12 h at 277 K with the protein (60 mg protease per milligram of protein) to remove the His 6 tag. Following TEV protease treatment, size-exclusion chromatography (HiLoad 26/60 Superdex 200 column, GE Healthcare) was performed with 10 ml TEV protease-treated unconcentrated protein to remove minor impurities and aggregates, and to exchange the buffer to 50 mM Tris pH 8.0, 125 mM NaCl. The protein was concentrated using Amicon Ultra-15 concentrators (Millipore) to 25 mg ml À1 (as determined by UV spectroscopy at 280 nm with a predicted extinction coefficient of 6990 M À1 cm À1 ), aliquoted and stored at 193 K.
Crystallization
Initial crystallization trials were carried out using the hanging-drop vapour-diffusion method in 48-well plates with a 1:1 ratio (total drop volume of 3 ml) of protein solution with commercially available crystallization screens from Hampton Research. Plates were kept in a vibration-free incubator at 296 K and crystallization drops from plates were observed after 24 h intervals. Conditions that gave rise to crystals were optimized by iteratively varying the pH and the concentrations of precipitants and salts and the protein.
X-ray diffraction and structure solution
Large diffraction-quality crystals (800 Â 100 Â 100 mm) were cooled in cryoprotectant comprised of 25% glycerol in crystallization solution. Diffraction data were collected at 100 K at a wavelength of 0.95370 Å on the MX2 beamline at the Australian Synchrotron. The collected diffraction data were indexed and integrated using iMosflm (Battye et al., 2011) and scaled in AIMLESS (Evans, 2006 (Evans, , 2011 . Phases were determined by molecular replacement using E. coli YdiI (PDB entry 1sbk; Northeast Structural Genomics Consortium, unpublished work; 38% identity; Fig. 1 ) as a search model in Phaser 
Results
Expression and purification
The overexpression of recombinant SaPaaI protein in E. coli BL21 (DE3) pLysS cells using auto-induction medium yielded approximately 30 mg of protein per litre of culture. The protein was highly soluble as determined by SDS-PAGE analysis of the whole cell Amino-acid sequence alignment of SaPaaI with the search model used in molecular replacement using ClustalX2. The sequence identity between the two proteins is approximately 38%. lysate, the soluble fraction and the purified protein from affinity chromatography (Fig. 2) . Elution of the protein occurred at approximately 300 mM imidazole and resulted in 95% purity. Removal of the His 6 affinity tag by TEV protease treatment reduced the size of the protein by 3 kDa, consistent with the size of the tag, and left three N-terminal vector-encoded amino acids (SDA). Sizeexclusion chromatography resulted in a single symmetrical peak, indicating a homogeneous protein preparation (Fig. 3) , and greater than 99% purity as judged by SDS-PAGE analysis. The SaPaaI protein was concentrated to 25 mg ml À1 and used for crystallization screening trials.
Crystallization and diffraction
Initial crystallization conditions were screened through sparsematrix screening using commercially available screens from Hampton Research. Ten conditions (Crystal Screen condition Nos. 4, 9, 14, 15, 18, 22, 33, 39, 40 and 46) gave rise to small crystals at 296 K after 24 h, all of which had the common precipitants of PEG 400, PEG 4000 or PEG 8000, with the exception of condition No. 4. Four conditions (Nos. 4, 9, 22 and 40) were optimized to produce diffraction-quality crystals with and without ligand (coenzyme A). Optimized condition No. 40 consisting of 24% PEG 4000, 100 mM sodium citrate pH 6.5, 12% 2-propanol produced large diffraction-quality crystals in the presence of 1 mM coenzyme A (CoA) ligand after 24 h at 296 K (Fig. 4) . A single crystal was cooled in a cryoprotectant incorporating 25% glycerol in the crystallization solution and X-ray diffraction data were collected at the Australian Synchrotron. The crystal diffracted X-rays to beyond 2.0 Å resolution (Fig. 5) . The crystal belonged to space group P12 
Figure 2
SDS-PAGE analysis (reducing gel). Lane A, Precision Plus Protein Standards (labelled in kDa). Lane B, whole cell lysate. Lane C, supernatant after centrifugation of the whole cell lysate. Lane D, flowthrough fraction after loading the supernatant onto the His column. Lane E, elution fraction after performing affinity chromatography (95% pure sample); the lower band represents the monomeric form of SaPaaI, whereas the upper band represents the dimeric form of SaPaaI. Lane F, elution fraction from gel-filtration chromatography (99% pure sample) following digestion with TEV protease to remove the His affinity tag. c = 60.74 Å , = 100.53 , and the data frames were integrated and scaled to 2 Å resolution using iMosflm v.1.0.5 and AIMLESS, respectively, with an R p.i.m. of 0.041 and 0.288 across all resolution shells and the outer resolution shell, respectively. The data-collection statistics are summarized in Table 1 . The data did not appear to be twinned as determined using POINTLESS from the CCP4 suite , and a value of 2.18 Å 3 Da À1 for the Matthews coefficient suggested the presence of four molecules in the asymmetric unit (Matthews, 1968) . The structure was solved by molecular replacement in Phaser (McCoy et al., 2007) using chain A (138 amino acids) of PDB entry 1sbk, with 38% amino-acid identity to SaPaaI, as a search model (LLG and TFZ of 557.4 and 14.5, respectively) . Model building and refinement produced a model with an R factor and R free of 17.3 and 22.0%, respectively, and the coordinates and structure factors have been validated and deposited in the Protein Data Bank as entry 4m20. Two CoA molecules and 192 water molecules are present. Six residues (SerÀ2, AspÀ1, Ala0, Met1, Leu123 and Lys124) are missing in chains A and D and five residues (SerÀ2, AspÀ1, Ala0, Met1 and Lys124) are missing in chains B and C of the final model. Full structural and functional characterization including activity and specificity assays, mutagenesis and crystallization with different ligands is currently being undertaken. SaPaaI crystals obtained using 24% PEG 4000, 100 mM sodium citrate pH 6.5, 12% 2-propanol, 1 mM coenzyme A after 24 h at 296 K.
Figure 5
X-ray diffraction image of an SaPaaI protein crystal, showing diffraction beyond 2 Å resolution.
